SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Quture International, Inc. (QUTR)

QUTR RSS Feed
Add QUTR Price Alert      Hide Sticky   Hide Intro
Moderator: inforthemoney2
Search This Board: 
Last Post: 4/23/2017 11:49:53 AM - Followers: 78 - Board type: Free - Posts Today: 2

 
     OPTIMAL


  Home | Contact Us | Login | Register

Share This...Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn
 
QualOptima is the
Empower
Q’s strategic technology platform empowers compliance with the new Joint Commission accreditation standards for FPPE-OPPE as well as regulatory requirements for many of the HITECH meaningful use measures and for prevention of readmissions and limitations for hospital acquired conditions (HAC’s); but QualOptima offers the extraordinary opportunities to exceed compliance while gaining new benefits for optimal clinical, financial and operational outcomes . . .
Compliance
Clinical Intelligence System to
QualOptima is the
Empower
Q’s technology with embedded clinical content, metrics and analytics strategically empowers providers and payers to thrive in the evolving healthcare environment . . .
Performance Measurement
Clinical Intelligence System to
QualOptima is the
Empower
Q’s innovative and first to market QualOptima technology strategically analyzes outcomes from Q’s constellation of evidence-based metrics. . .
Optimal Outcomes Analytics
Clinical Intelligence System to
QualOptima is the
Empower
Q’s innovative and first-to-market QualOptima technology bundled with Q’s QualVal consulting services provides our clients with exponentially value expert resources to achieve optimal clinical, financial and operational outcomes through actionable clinical wisdom . . .
Expert Resources
Clinical Intelligence System to
QualOptima is the
Empower
Q’s technology is the first-to-market solution to meet the strategic imperative for healthcare providers to transform from fee-for-service and optimized billing strategies and software to a value-driven revenue model empowered by QualOptima . . .
Value-Driven Revenue
Clinical Intelligence System to
 
 
 
 
 
 
 
 
 
 

http://www.quture.com/


Quture International, Inc
 
OTCQB Logo

Contact Info

     

Quture International, Inc.
200 Magnolia Avenue
Daytona Beach, FL 32114 

 

Phone: (407) 377-6649

Email: info@quture.com






 

View larger map












Share Structure
OS: 2.5B Shares.
FLOAT: 375M Shares
(2.5B x .85 = 2.125B, 2.5M - 2.125B = 375M)

 

SHARES FROM THE MERGER ARE RESTRICTED

The securities described in Item 1.01 above were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act.  At the time of their issuance, the securities will be deemed to be restricted securities for purposes of the Securities Act, and the certificates representing the securities shall bear legends to that effect.  The securities may not be resold or offered in the United States without registration or an exemption from registration.


INSIDERS OWN 85% (AUG 9, 2011)
As a result of the Exchange, Quture became a wholly-owned subsidiary of the Registrant. Following the consummation of the Exchange, the shareholders of Quture will beneficially own approximately eighty-five percent (85%) of the issued and outstanding Common Stock of the Registrant.

So On TOP of the Restriction these shares can only be sold per insider trading rules which is something along the lines of 1% of the volume of the previous 10 trading days, etc)
 


ABOUT  QUTURE

Quture is an emerging healthcare knowledge solution company positioned to transform health and healthcare by developing the standard in measuring clinical performance. The Company's products and services will become the essential technology and tool to improve care and health, while reducing costs. The demand to measure performance is coming from all stakeholders in healthcare involved in both payment and delivery. Measuring performance is now mandatory and is the new foundation of how providers are reimbursed, granted privileges to practice in hospitals, and, in the near future, selected by patients for their care.

Quture is not a software company. Quture is the company that makes the best software in the world better. We know what to find, where to find it, and what to do with it once you find that data in disparate electronic data sources in healthcare organizations. The Company licenses the application of performance measures delivered in a software platform creating the most powerful clinical knowledge database in the world. Quture knows what payers want to pay for, and what they do not want to pay for, and the clinical knowledge to support payment systems while improving care.

Quture's mission statement is to become the Gold Standard in Healthcare Performance Measurement. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that these performance measures are the "transformative tool" that reduce medical cost and improve quality of care. Q'uture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions as a leader and innovator in measuring clinical performance. Quture plans include developing a revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases



G. Landon Feazell, Chairman & CEO

Landon Feazell is Chairman and Chief Executive Officer of Quture, Inc., positioned to become a major force in the transformation of health care and personal health. The company leverages over 35 years of measuring performance & outcomes and improving clinical quality and patient safety to anticipate the needs of providers to chart the future of quality in health care. The core capabilities of Quture are embedded in software and technology to convert data to clinical knowledge to achieve evidence-based, predictive clinical care. Mr. Feazell is nationally recognized for his leadership, innovation, and expertise in measuring clinical performance, pioneering proactive clinical risk management and patient safety and physician peer review processes. His companies have developed and implemented systems and processes in hundreds of hospitals, hospital corporations and trusts, university health systems, health maintenance organizations, large and small physician practices, federal and state governmental agencies, and health and liability insurance companies throughout the United States.

Mr. Feazell received a Bachelor of Science degree in zoology from Duke University (1965). His extensive graduate studies are in medical sciences at the West Virginia University Medical Center (1965-1967), where he was a teaching fellow, conducting research in mycology and its relationship to leukemia and preventive medicine under the direction of Ernest W. Chick, M.D., Ph.D. His graduate studies further included law at the University of Denver, College of Law (1967-1970), where he was student assistant to the deans. He served as Chairman of the National Conference of Law Reviews (1968-69) and after graduation has served as Chairman of the Board Council of Community Mental Health Centers and chaired board training grants for these centers for a federal region. His community service includes chairing many public education initiatives for Jefferson County Board of Education and successful political campaign cabinets for Governor and United States Senator in Colorado. He is widely published in professional articles, and he lectures, teaches, and participates on national expert panels at universities, professional organizations, private corporations, and forums and seminars and has taught at the undergraduate and graduate level at several universities.


 

Janice J. Ophoven, MD, Associate Medical Director (QualOptima)

Dr. Janice Ophoven is a pediatric forensic pathologist with over thirty years of clinical, administrative and quality improvement experience. She is board certified in Pathology, Forensic Pathology, Quality Assurance and Utilization Review. Dr. Ophoven has focused her clinical practice on understanding child abuse and injury to children.

Dr. Ophoven is an internationally recognized and a court-certified medical expert in pediatric forensic pathology. She has consulted and/or testified in civil and criminal cases in the US and abroad for both defense and prosecution when injury or death to a child has occurred. For these cases and as a consultant to Medical Examiners/coroners, physicians, law enforcement, and legal professionals she has been asked to determine the cause and manner of a child's injury or death.

She is also a consultant and nationally recognized speaker and educator on Forensic Pathology as well as on quality improvement of health care systems. She has worked with physicians, clinicians and hospital systems at organizations such as, Children's Hospital-St. Paul, MN; and Allina Health System, MN: Montefiore Hospital (Albert Einstein University), NY to improve quality system-wide.

Through her years of experience, Dr. Ophoven has pioneered an innovative and successful evidence-based model that draws on medical science and practicing clinicians to identify risk and challenge barriers to successful medical care.

In 1981, Dr. Ophoven founded her firm specializing in pediatric forensic pathology services. Her work has included cases of Munchausen's Syndrome By Proxy (MSBP), infanticide, sexual misuse, infant apnea/SIDS, suffocation, and accidental and inflicted head trauma. Her work requires both in-depth knowledge of medical sciences and forensics including: General Pediatric Pathology and Laboratory Medicine, Developmental and Gestational Pathology, as well as Pediatric Autopsy and Injury Analysis, Pediatric Laboratory Medicine, Pediatric Hematopathology, and Pediatric Pulmonary Disease.


 

Keith Candiotti, MD, Associate Medical Director (QSurg)

  • Chief of the Division of Perioperative Medicine, Department of Anesthesiology, University of Miami Miller School of Medicine
    Vice Chairman of Clinical Research, Department of Anesthesiology, University of Miami School of Medicine
    Associate professor of anesthesiology
    Miami, Florida

Dr. Keith Candiotti is a graduate of the University of Miami Miller School of Medicine, where he completed a residency in internal medicine in 1992 and a residency in anesthesiology in 1994 and went on to join the Department of Anesthesiology. He currently serves as Chief of the Division of Perioperative Medicine and Vice Chairman of Clinical Research within the department. Additionally, he has coappointments in the departments of Internal Medicine, Urology, and Obstetrics and Gynecology.

Dr. Candiotti has conducted numerous clinical trials, including US Food and Drug Administation studies in the areas of postoperative nausea and vomiting (PONV), pain, consciousness monitoring, and other various clinical areas. His personal research interests are in the areas of perioperative inflammatory responses; pharmacogenomics and how it relates to pain and perioperative outcomes, PONV, and preoperative evaluation; and the management of patients exposed to weapons of mass destruction. He is a member of the American Society of Anesthesiologists Committee on Research and was recently appointed as Chairman of the Society of Ambulatory Anesthesia Research Committee.

Dr. Candiotti has published numerous articles and abstracts at various medical meetings. He currently lectures both in the United States and around the world on topics related to his areas of interest.


 

Judith K. Daugherty, RN, PhD, Director, Multi-Disciplinary Clinical Content

Dr. Daugherty co-founded Excelcare, Inc., in 1984 and serves as its President/CEO. The Excelcare product is the leading nursing care plan and documentation system for nursing expected outcomes. The software introduced the innovative nursing software technology for five functions: Planning/Clinical Pathways, Documenting, Quality Management, Staffing and Costing. The Excelcare product has been successfully marketed and implemented in the USA, Australia, Asia, and Europe. Dr. Daugherty has served in a consultation role for Lockheed Martin Federal Systems Health Division, CareGroup System (Boston) and Price Waterhouse Senior Management Consultant in hospital and nursing engagements. Prior to Excelcare, she was Associate Administrator Mercy Hospital (PA). She has organized, sponsored and/or presented at domestic and international professional education seminars for all levels of healthcare professionals, as well as being Adjunct Professor (Nursing): Hunter College (NY, NY) and University of Pittsburgh (PA) and Professor (Masters Nursing Administration Program): Duquesne University (Pittsburgh, PA). Her community service includes being Past Chairman of PA Board of Directors, American Heart Association.


 


RECENT NEWS:

Tuesday, November 13, 2012

     .    
Quture Recruits Healthcare Visionary and Accomplished Expert to Strengthen Distinguished Management Team      MWUS(Tues, Nov 13)

Monday, August 27, 2012

       .
Quture/TCLN QualOptima Product Business Case Expands Focus to Patient-Centered Personalized Medicine Marketwire(Mon, Aug 27)

Wednesday, August 8, 2012  

       .
Quture/TCLN QualOptima Product on Target With Hospital Urgent Needs to Acquire Clinical Analytics Tools  Marketwire(Wed, Aug 8)

Monday, July 30, 2012

     .
Quture/TCLN Announces Successful Completion Of Interdisciplinary Product At Niagra Falls Memorial Hospital Preparing For Comm..  PRNUS(Mon, Jul 30)


Wednesday, July 11, 2012

     .
Quture/TCLN & Springhill Medical Center Jointly Announce Sale of Software License to Qualoptima  Marketwire(Wed, Jul 11)

Thursday, June 21, 2012

     . 
Quture/TCLN Issues Shareholder Letter and Update Marketwire(Thur,  Jun 21)

Tuesday, June 12, 2012

      . Quture International, Inc. / TCLN Announces Pre-Launch Completion of QualOptima Commercial Product Marketwire(Tues, Jun 12)

Monday, May 14, 2012

     .  Quture/TCLN Announces Formation of Subsidiary for European Operations Marketwire(Mon, May 14)

Tuesday, March 27, 2012

     .  Quture International, Inc. / TCLN Announces Successful Completion to QualOptima Product Demonstration. Marketwire(Tues, Mar 27)
  
Thursday, March 15, 2012

        .Techs Loanstar, Inc. Announces Corporate Name Change to Quture International, Inc.Marketwire(Thurs, Mar 15)

Tuesday, December 20, 2011

      .  Quture/TCLN Annousnces First Commercial  Application on Intersystems Platform  Marketwire(Tues, Dec 20)

Thursday, November 10, 2011

Monday, September 26, 2011

Tuesday, September 6, 2011

Tuesday, August 23, 2011

Monday, July 25, 2011

Tuesday, June 28, 2011

Monday, June 27, 2011

 
 





 
 
 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
QUTR
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#6045  Sticky Note QUTR investors have asked about Quture's participation in Tobinn 02/27/17 02:02:06 PM
#6185   Maybe I can save you some trouble. I Tobinn 04/23/17 11:49:53 AM
#6182   That's funny. Still, let's recall a few gauvdog 04/21/17 03:55:13 PM
#6181   thats fantastic PT128 04/21/17 12:28:56 PM
#6180   Finally your opinion on quture given in its Tobinn 04/21/17 10:56:20 AM
#6178   Tobin is no pumper. IMO he is a chance4 04/21/17 08:25:45 AM
#6177   No problem! I like calling out pumpers!! gauvdog 04/21/17 06:06:07 AM
#6176   Yeah the .002 was millions of shares going Tobinn 04/20/17 12:45:00 AM
#6175   Yaaaaaaaawwwwwwwwwwwwnnnnnnnnnnnnnnnnn!!! Fido 04/19/17 12:45:34 PM
#6174   ...but we went from .0001 to .002 and gauvdog 04/18/17 05:40:08 AM
#6173   And another action packed week passes by. Fido 04/13/17 06:45:54 PM
#6172   HFACS training in Daytona, FL less than 2 inforthemoney2 04/12/17 11:12:13 AM
#6171   That, and the result of a tremendous amount chance4 04/11/17 06:52:02 PM
#6170   That'd be nice, but I've been through quite gauvdog 04/11/17 05:36:14 PM
#6169   Was talking about the 2 plus months following chance4 04/10/17 11:49:54 AM
#6168   Or, old investors possibly seeing a buying opportunity. gauvdog 04/10/17 11:03:35 AM
#6167   At this point in time, for those of Fido 04/10/17 09:21:26 AM
#6166   I don't remember that as a pump and chance4 04/10/17 06:44:08 AM
#6165   Excellent point we are sitting in the middle PT128 04/09/17 10:36:34 PM
#6164   I remember the pump of that. I don't Tobinn 04/09/17 09:05:09 PM
#6163   Regrettably much of that "high" volume was from Fido 04/09/17 08:18:56 AM
#6162   :) Good one. Fido 04/09/17 08:17:16 AM
#6161   Agreed!!!! Last time the stock made a significant chance4 04/08/17 08:04:29 PM
#6160   Give this stock a few more weeks and BIGDADMAC 04/08/17 07:01:23 PM
#6159   You first. gauvdog 04/08/17 05:42:30 PM
#6158   In between waiting for something of substance to Tobinn 04/08/17 01:56:38 PM
#6157   ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ.............. Fido 04/06/17 11:38:50 AM
#6156   Wow, this is the most excited I've been Fido 04/05/17 02:14:56 PM
#6155   Such excitement generated by LF, more tweets, we Fido 04/05/17 02:14:32 PM
#6154   Lets go LF show us the completed software inforthemoney2 04/04/17 01:25:56 PM
#6153   The positives here is that no one is BIGDADMAC 04/03/17 02:32:01 PM
#6152   HELP! I can't keep up with all Fido 03/31/17 12:09:24 PM
#6151   It could be that HFACS has a 2 inforthemoney2 03/30/17 08:30:47 AM
#6150   That's quite a claim you are making. gauvdog 03/30/17 06:24:42 AM
#6149   It sure is really quiet around here, the BIGDADMAC 03/28/17 10:54:58 PM
#6148   Come on QUTR, we need to know just Fido 03/28/17 07:47:32 PM
#6147   I see the rocket is still on the Fido 03/28/17 07:47:19 PM
#6146   That's much like where I am at. gauvdog 03/28/17 06:30:17 AM
#6145   I'm definitely gambling here. I can't see Fido 03/27/17 06:16:50 PM
#6144   Excellent post. Correct both companies serve 2 completely chance4 03/27/17 05:36:23 PM
#6143   Well, the intersystems deal is not one that Tobinn 03/27/17 05:16:16 PM
#6142   What you are suggesting is not a popular gauvdog 03/27/17 04:23:34 PM
#6141   Is there really any thoughts on whether HFACS Fido 03/27/17 03:45:23 PM
#6140   I have no idea about filings. My guess Tobinn 03/24/17 06:54:58 PM
#6139   Tbinn, I following your positive posts, however we millions213 03/24/17 11:43:28 AM
#6138   Still waiting on LF to produce the fins. inforthemoney2 03/24/17 11:04:45 AM
#6137   Any body on the board knows about the millions213 03/24/17 11:01:03 AM
#6136   Here is some HFCAS News working with the inforthemoney2 03/24/17 10:34:01 AM
#6135   And one of the largest gains in the gauvdog 03/24/17 06:12:36 AM
#6134   If you want you can always call, text, BIGDADMAC 03/23/17 02:10:51 PM
#6133   I'm there with you on that. Wish I inforthemoney2 03/23/17 02:09:36 PM
PostSubject